Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Hoth Therapeutics, Inc. (HOTH : NSDQ)

• Company Description    Hoth Therapeutics Inc. is a development stage biopharmaceutical company. It focused on therapeutics for patients suffering from indications such as atopic dermatitis, also known as eczema. The company's BioLexa(TM) Platform is a proprietary, patented drug compound platform. Hoth Therapeutics Inc. is based in New York, United States. Number of Employees: 3

• Price / Volume Information    Yesterday's Closing Price: $1.17 Daily Weekly Monthly 20 Day Moving Average: 2,974,517 shares Shares Outstanding: 13.21 (millions) Market Capitalization: $15.45 (millions) Beta: 0.67 52 Week High: $3.80 52 Week Low: $0.58 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 25.81% 20.35% 12 Week 48.12% 20.84% Year To Date 56.40% 48.25%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 1177 Avenue of the Americas 5th Floor Suite 5066 - New York,NY 10036 USA ph: 646-756-2997 fax: - investorrelations@hoththerapeutics.com https://hoththerapeutics.com

• General Corporate Information    Officers Robb Knie - President; Chief Executive Officer and Director David Briones - Chief Financial Officer Wayne Linsley - Director David B. Sarnoff - Director Graig Springer - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 44148G204 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/08/25 Share - Related Items Shares Outstanding: 13.21 Most Recent Split Date: 10.00 (0.04:1) Beta: 0.67 Market Capitalization: $15.45 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.27 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.97 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/08/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.34 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 41.30% vs. Previous Quarter: 15.62% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - - 03/31/25 - -109.18 12/31/24 - -103.82 ROA 06/30/25 - - 03/31/25 - -100.22 12/31/24 - -94.82 Current Ratio 06/30/25 - - 03/31/25 - 15.09 12/31/24 - 9.20 Quick Ratio 06/30/25 - - 03/31/25 - 15.08 12/31/24 - 9.20 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Book Value 06/30/25 - - 03/31/25 - 0.88 12/31/24 - 0.86 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00

Powered by Zacks Investment Research ©